Healthcare / BiotechnologyNasdaqCM
$3.31
+0.16 (+5.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-2.8M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$8M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-36.2%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-76.8%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.0M · net income $-2.7M · FCF $-2.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $3.0M | $3.0M | $2.5M | $2.5M | $1.7M | $1.2M | $436942.00 | $17066.00 | $0.00 | $7.6M | $3.0M | $0.00 | $0.00 | $1.0M | $293603.00 | — |
| Net Income | $-2.7M | $-2.7M | $-4.0M | $-4.1M | $-6.6M | $-5.6M | $-10.9M | $-12.8M | $-7.3M | $-3.6M | $-54.2M | $-12.5M | $-14.3M | $-8.6M | $-6.3M | — |
| EBITDA | $-2.8M | $-2.8M | $-4.2M | $-4.5M | $-6.7M | $-5.7M | $-13.9M | — | — | — | — | $-9.8M | $-12.8M | $-8.6M | — | — |
| EPS | -1.58 | -1.58 | -2.57 | -2.71 | -4.61 | -5.50 | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | 100.0% | 84.7% | — |
| Operating Margin | -95.2% | -95.2% | -168.2% | -177.8% | -393.6% | -495.1% | -3189.8% | -75511.7% | — | -47.1% | -1581.0% | — | — | -861.3% | -2160.8% | — |
| Net Margin | -90.1% | -90.1% | -158.4% | -162.8% | -383.9% | -486.4% | -2493.1% | -74856.6% | — | -47.4% | -1806.9% | — | — | -857.9% | -2155.4% | — |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -2.29 |
| Current Ratio | 7.93 | 7.93 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-2.3M | $-2.3M | $-2.8M | $-4.1M | $-5.1M | — | — | — | $-6.5M | $1.5M | $-8.8M | — | — | $-6.1M | $-6.4M | — |
| Returns | ||||||||||||||||
| ROE | -36.2% | -36.2% | -65.9% | -42.2% | -48.0% | -30.7% | -89.2% | -74.2% | -73.6% | -25.1% | -335.2% | -189.3% | -136.5% | -68.0% | -30.5% | — |
| Valuation | ||||||||||||||||
| P/B | 0.76 | 0.76 | 1.09 | 0.54 | 0.36 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | 19.0% | 19.0% | -1.6% | 48.8% | — | 165.6% | 2460.3% | — | -100.0% | 152.8% | — | — | -100.0% | 240.6% | — | — |
| EPS Growth | 38.5% | 38.5% | 5.2% | 41.2% | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.57 → -1.58
Residual
+10.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.